FDA Approves Novartis' Cosentyx for Polymyalgia Rheumatica

The U.S. Food and Drug Administration (FDA) has granted approval to Novartis (NVS) for its biologic drug, Cosentyx (secukinumab) 150 mg, specifically for treating adults with polymyalgia rheumatica. This indication is intended for patients who have not responded adequately to corticosteroids or are unable to tolerate reductions in steroid dosages. This approval marks a significant milestone as Cosentyx becomes the first and only anti-IL-17 biologic approved for this specific condition. The decision provides a new therapeutic option for a patient population that often struggles with the side effects of long-term corticosteroid use.

2 articles from 2 sources · updated

Coverage